Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00694590 · ClinicalTrials.gov registry record · Phase 1

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Genzyme, a Sanofi Company.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
3
Study locations

NCT00694590 is a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 24 participants, below the 191-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00694590, a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), has completed, sponsored by Genzyme, a Sanofi Company.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this research study is to determine if plerixafor can make CLL/SLL (Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma) cells more sensitive to being killed by rituximab, an anti-cancer drug that is commonly used in treating CLL and SLL. In this study, plerixafor will be added to standard treatment with rituximab. Subjects will be monitored to see how well they tolerate the use of these drugs together and how well they work to treat the leukemia. The primary objective is to determine the maximum tolerated dose (MTD) of plerixafor when combined with rituximab as treatment for previously treated patients with CLL or SLL.

Conditions Studied

Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)

Interventions

  • DRUG plerixafor

Study Locations (3)

California

  • UCSD Moores Cancer Center - La Jolla

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Texas

  • UTMD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-06
Est. Completion 2011-09
Phase Phase 1

Sponsor

Genzyme, a Sanofi Company

196 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00694590

The ClinicalTrials.gov registry entry for NCT00694590 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (87% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which plerixafor is the first listed.

NCT00694590 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT00694590 about?

NCT00694590 is a clinical study titled "Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". The purpose of this research study is to determine if plerixafor can make CLL/SLL (Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma) cells more sensitive to being killed by rituximab, an anti-cancer drug that is commonly used in treating CLL and SLL. In this study, plerixafor will be added t...

What is the current status of trial NCT00694590?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-06. Estimated completion is 2011-09.

What conditions does trial NCT00694590 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).

What interventions are being tested in trial NCT00694590?

The interventions under investigation include: plerixafor (DRUG).

Who is sponsoring clinical trial NCT00694590?

This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00694590 being conducted?

This trial has 3 study locations across California, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia (CLL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia (CLL)

All registered trials for this condition

Small Lymphocytic Lymphoma (SLL)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.